PAM
ALDX icon

Panagora Asset Management’s Aldeyra Therapeutics ALDX Stock Holding History

Panagora Asset Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-72,059
Closed -$276K – 1150
2025
Q2 		$276K Buy
72,059
+21,605
+43% +$55.9K ﹤0.01% 959
2025
Q1 		$290K Sell
50,454
-125,554
-71% -$742K ﹤0.01% 943
2024
Q4 		$878K Buy
176,008
+39,658
+29% +$203K ﹤0.01% 688
2024
Q3 		$735K Buy
136,350
+76,052
+126% +$362K ﹤0.01% 813
2024
Q2 		$200K Buy
+60,298
New +$236K ﹤0.01% 1138
2021
Q3 		– Sell
-460
Closed -$5K – 1719
2021
Q2 		$5K Sell
460
-103
-18% -$1.24K ﹤0.01% 2475
2021
Q1 		$7K Hold
563
– – ﹤0.01% 2492
2020
Q4 		$4K Buy
+563
New +$3.95K ﹤0.01% 2507
2020
Q2 		– Sell
-39,632
Closed -$98K – 2557
2020
Q1 		$98K Buy
39,632
+20,184
+104% +$90.8K ﹤0.01% 1702
2019
Q4 		$113K Buy
+19,448
New +$112K ﹤0.01% 1769

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Panagora Asset Management's ALDX Position: Q3 2025 in Review

Panagora Asset Management sold out of Aldeyra Therapeutics (ALDX) in Q3 2025, closing a stake of 72,059 shares — an estimated $276K sold.

Panagora Asset Management first reported a position in ALDX in Q4 2019 and held it in 10 quarters. The position peaked at $878K in Q4 2024. 131 funds tracked by Wall St. Rank hold ALDX as of Q3 2025.

  • Panagora Asset Management reported no remaining Aldeyra Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Panagora Asset Management sold 72,059 Aldeyra Therapeutics shares in Q3 2025, an estimated $276K.
  • Panagora Asset Management first reported a position in Aldeyra Therapeutics in Q4 2019 and held it in 10 quarters.
  • Panagora Asset Management's Aldeyra Therapeutics position peaked at $878K in Q4 2024.
  • 131 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2025.

Based on Panagora Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.